@article{d1b39c11-83a1-4d96-b812-a4558ae8d104,
  author       = {{Abel, Edvard and Östling, Päivi and Hult, Ebba Hallersjö and Kulbacka, Katarzyna and Babacic, Haris and Baan, Annika and Carneiro, Ana and De Petris, Luigi and Fagman, Henrik and Friesland, Signe and Frisell, Oskar and Hellström, Mats and Lindahl, Gabriel and Carlsson, Katarina Steen and Amborero, David and Valachis, Antonios and Öhlund, Daniel and Lehtiö, Janne and Rosenquist, Richard and Edsjö, Anders and Botling, Johan and Bäckvall, Helena and Fred, Rikard and Garvin, Stina and Hallqvist, Andreas and Heidenblad, Markus and Catela-Ivkovic, Tina and von Sydow, Anita Koskela and Köhn, Linda and Lagerhorn, Rozina Caridha and Löfgren, Maja and Melin, Malin and Isaksson-Mettävainio, Martin and Moens, Lotte N.J. and Ny, Lars and Nord, Helena and Olauson, Hannes and Qvick, Alvida and Rapisarda, Stefano and Tham, Emma}},
  issn         = {{0284-186X}},
  keywords     = {{biomarker profiling; cancer genomics; drug repurposing; infrastructure; multimodal analysis; platform trial; Precision medicine; PRIMEROSE consortium; proteomics; Sweden; targeted therapy}},
  language     = {{eng}},
  pages        = {{268--272}},
  publisher    = {{Taylor & Francis}},
  series       = {{Acta Oncologica}},
  title        = {{The FOCU.SE trial : a nationwide Swedish drug repurposing protocol and research framework}},
  url          = {{http://dx.doi.org/10.2340/ao.v65.45355}},
  doi          = {{10.2340/ao.v65.45355}},
  volume       = {{65}},
  year         = {{2026}},
}